Loading
Adding the PD-1 antibody toripalimab to gemcitabine and cisplatin lengthened the time before metastatic nasopharyngeal cancer progressed by about four months, and later improved survival, making chemo-immunotherapy the first-line standard.
International randomised double-blind placebo-controlled phase 3 trial of 289 patients with recurrent or metastatic nasopharyngeal carcinoma assigned to toripalimab or placebo with gemcitabine and cisplatin, followed by toripalimab or placebo maintenance.
Median progression-free survival was 11.7 months with toripalimab against 8.0 months (hazard ratio 0.52) at the interim analysis, with benefit regardless of PD-L1 expression; the final analysis (JAMA 2023) showed improved overall survival. Toripalimab was approved in China in 2021 and by the FDA in 2024.
PD-1 blockade with gemcitabine and cisplatin is the first-line standard for recurrent or metastatic nasopharyngeal carcinoma, and the first immunotherapy approved for this cancer in the United States.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Gemcitabine + cisplatin.
Shares JUPITER-02, Recurrent and metastatic nasopharyngeal carcinoma, Gemcitabine + cisplatin.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Gemcitabine + cisplatin.
Shares JUPITER-02, Toripalimab.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Toripalimab.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Gemcitabine + cisplatin, Toripalimab.
Shares JUPITER-02, Toripalimab.